These are exciting times for biotech business Complement Therapeutics, which stands on the cusp of an important milestone in ...

An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising ...

Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

The FDA has granted Orphan Drug designation to riliprubart for the investigational treatment of AMR in solid organ transplantation.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Riliprubart for the investigational treatment of antibody-mediated rejection ...

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

As a result, complement activation initiated by CRP efficiently results in recruitment of the opsonic function of the system, but does not result in its proinflammatory and membrane-damaging effects.